---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-017274"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T13:16:31.600534+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INmune Bio FY2022 net loss $27.3M; XPro AD trial under FDA clinical hold

## Summary
- Net loss $27.3M vs $30.3M in 2021; R&D expense $17.1M; cash $52.2M at Dec 31, 2022.
- FDA clinical hold on XPro AD trial in US continues; enrollment ongoing in Australia and Canada.
- Phase 2 AD trial topline readout expected 2H 2024; trial consolidated to include MCI patients.
- IND for INKmune in mCRPC to be filed March 2023; Phase I/II trial planned.
- Received ~$6.4M in R&D rebates from Australia and UK; will reinvest in recruitment.

## SEC filing metadata
- accession: 0001213900-23-017274
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390023017274/0001213900-23-017274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390023017274/ea174635-8k_inmunebio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-017274
- JSON: https://secwatch.observer/filing/0001213900-23-017274.json
- Plain text: https://secwatch.observer/filing/0001213900-23-017274.txt

## Key facts
- Earnings Releases
  Inmune Bio, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2022 and provides a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390023017274/0001213900-23-017274-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.